Your session is about to expire
← Back to Search
Other
MHU650 for Retinal Vein Occlusion
Phase 1
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1, 2, 5, 15, 29, 43 and 60
Awards & highlights
Summary
This trial tests a new eye injection treatment called MHU650 for people with macular edema. The goal is to see if it can reduce eye swelling and improve vision by delivering the medicine directly to the affected area.
Eligible Conditions
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Age-Related Macular Degeneration
- Macular Edema
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 1, 2, 5, 15, 29, 43 and 60
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1, 2, 5, 15, 29, 43 and 60
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from baseline in Best Correct Visual Acuity (BCVA ) by dose level and timepoint - Study Eye
Change from baseline in Central subfield thickness (CSFT) (µm) in the study eye by dose level and timepoint
Change from baseline in Intraocular pressure (IOP) (mmHg) in the study eye by dose level and timepoint
+1 moreSecondary outcome measures
Pharmacokinetics of single dose of MHU650 - AUCinf
Pharmacokinetics of single dose of MHU650 - AUClast
Pharmacokinetics of single dose of MHU650 - Cmax
+2 moreTrial Design
4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
Cohort 4, open-label, non-randomized, single administration
Group II: Cohort 3Experimental Treatment1 Intervention
Cohort 3, open-label; non-randomized, single administration
Group III: Cohort 2Experimental Treatment1 Intervention
Cohort 2; open-label, non-randomized, single administration
Group IV: Cohort 1Experimental Treatment1 Intervention
Cohort 1; open-label, non-randomized, single administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MHU650
2020
Completed Phase 1
~30
Find a Location
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor
2,874 Previous Clinical Trials
4,199,970 Total Patients Enrolled
14 Trials studying Retinal Vein Occlusion
33,597 Patients Enrolled for Retinal Vein Occlusion
Share this study with friends
Copy Link
Messenger